Status:
COMPLETED
CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation
Lead Sponsor:
Zimmer Biomet
Collaborating Sponsors:
Zimmer Dental
Conditions:
Alveolar Ridge Defect
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, multi-center study to evaluate the use of CopiOs Pericardium Membrane, a bovine xenograft, with use of Puros Cancellous Particulate Allograft, for the augmentation of localized ...
Detailed Description
The study will evaluate the use of CopiOs Pericardium Membrane (CopiOs Pericardium), a bovine xenograft, with the use of Puros Cancellous Particulate Allograft (Puros Cancellous), a mineralized allogr...
Eligibility Criteria
Inclusion
- Male or female, of any ethnicity, between 18 and 99 years of age
- Health status of P1(ASA I) or P2 (ASA II), as classified by the American Academy of Anesthesiologists
- Able to communicate with the investigator and read, understand, and sign the informed consent form
- No evidence of active moderate or severe periodontitis
- Must be available for multiple follow-up visits for the duration of the study
- The study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5 mm in its smallest buccolingual dimension as measured by ridge-mapping calipers (#RIDGE-CALIPER, Salvin Dental Specialties, Inc., Charlotte, NC).
Exclusion
- Inability or failure to maintain adequate oral hygiene
- Women who are bread-feeding, pregnant, or who intend to become pregnant during this study period. Women of childbearing potential should be practicing a medically accepted method of birth control
- Patients with unstable systemic diseases
- Patients with compromised immune system (e.g. uncontrolled diabetes, etc.) or unstable bleeding disorder
- Patients with active infectious diseases (e.g. hepatitis, tuberculosis, HEV, etc.)
- Patients with a mental disability that may hinder participation in the study (e.g. inability to follow through with oral hygiene instructions, postoperative instructions, follow-up commitments, etc.)
- Patients taking steroid medications or undergoing other immunosuppressive therapy
- Radiation, cancer therapy, and/or radiation specifically at the oral cavity within the last 6 months
- History of previous ridge augmentation at the site of interest
- Augmentation sites with localized pathology
- Patient who has participated in a clinical trial within 30 days of being enrolled in this study, is currently enrolled in another study, or plans to enroll in another study before the completion of of this study.
- Unresolved oral pathologies (e.g. periodontal disease, caries, etc.)
- Medications or conditions contraindicated for bone regeneration: methotrexate, corticosteroids, history of bisphosphonate use, cyclosporine-A, etc.
- Patients who have more than a minimal tobacco use (e.g. \>10 cigarettes per day)
- Other conditions the investigator may feel would inhibit the patient from being a good candidate for this study or which are contraindicated in the Directions for Use.
- Note: Careful consideration should be given to alternative therapies prior to performing bone grafting in patients who have severe endocrine-induced bone diseases (e.g.hyperparathyroidism), or who are undergoing current therapy with drugs that intervene in calcium metabolism.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00889265
Start Date
June 1 2009
End Date
December 1 2011
Last Update
August 11 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver School of Dental Medicine
Aurora, Colorado, United States, 80045
2
Indiana University
Indianapolis, Indiana, United States, 46202
3
University of Texas Health Sciences Center at Houston
Houston, Texas, United States, 77030
4
University of Texas Health Sciences Center at San Antonio
San Antonio, Texas, United States, 78229-3900